Reducing Brain Damage in Acute Stroke with a New Blood Substitute
Mitigation of Cerebral Infarct Growth in Acute Ischemic Stroke Using a Novel Blood Substitute
This project explores a new blood substitute to help protect brain cells and limit damage after an acute ischemic stroke.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11143286 on NIH RePORTER |
What this research studies
When an ischemic stroke happens, brain cells can die very quickly, and the amount of damage varies greatly among individuals. This project aims to test a new medication called Sanguinate®, which is designed to improve blood flow to affected areas and deliver oxygen to oxygen-deprived brain tissue. By boosting the body's natural ability to create new blood vessel connections and providing oxygen, this approach seeks to reduce the overall size of the stroke damage. It also hopes to lessen injury that can occur when blood flow is restored after a clot is removed.
Who could benefit from this research
Good fit: This research is ultimately intended for patients experiencing an acute ischemic stroke, especially those who might benefit from improved oxygen delivery and reduced brain cell death.
Not a fit: Patients with other types of stroke, such as hemorrhagic stroke, or those without an acute ischemic event would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this new treatment could significantly reduce the amount of brain damage experienced by patients after an acute ischemic stroke, potentially leading to better recovery.
How similar studies have performed: Sanguinate® is an investigational agent, but its components and mechanisms of action are based on existing understanding of oxygen delivery and anti-inflammatory effects.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Carroll, Timothy J — University of Chicago
- Study coordinator: Carroll, Timothy J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.